As synaptic dysfunction is an early manifestation of Alzheimer disease (AD) pathology, magnetoencephalography (MEG) is capable of detecting disruptions by assessing the synchronized oscillatory activity of thousands of neurons that rely on the integrity of neural connections. MEG findings include slowness of the oscillatory activity, accompanied by a reduction of the alpha band power, and dysfunction of the functional networks. These findings are associated with the neuropathology of the disease and cognitive impairment. These neurophysiological biomarkers predict which patients with mild cognitive impairment will develop dementia. MEG has demonstrated its utility as a noninvasive biomarker for early detection of AD.
Keywords: Alzheimer disease; Functional connectivity; Magnetoencephalography; Mild cognitive impairment; Power; Preclinical stages; Prodromal stages.
Published by Elsevier Inc.